Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 345 participants.
Also called NCT02988115
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 345 participants
- Sponsor
- Registry
-
NCT02988115
-
- Other papers using this trial's data
- Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT02988115. Randomized; triple masking; primary purpose treatment. Start 2016-11-16 (actual); primary completion 2018-03-16 (actual). Results posted on 2020-04-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
- Acronym
- CLEAR Serenity
- Condition
- Hypercholesterolemia
- Condition
- Atherosclerotic Cardiovascular Disease
- Condition
- Statin Adverse Reaction
- Intervention (Drug)
- bempedoic acid
- Intervention (Other)
- placebo
- Lead sponsor
- Esperion Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct02988115- Content hash
b9c09a686c35728347256f62502993edb6d1ff2a2732ccd7d34db6b58d674f85